 NEW YORK, March 31, 2021 PRNewswire -- Actinium Pharmaceuticals, Inc. NYSE AMERICAN: ATNM Actinium or the Company today announced that it will be participating in the Cell Gene Meeting on the Mediterranean, which is being held virtually April 6 9, 2021, where it will feature its Iomab-ACT program. Iomab-ACT is an extension of Actiniums lead program, Iomab-B, which is being studied in a pivotal Phase 3 trial for targeted myeloablative conditioning prior to a bone marrow transplant. 